NEWS, PRESS RELEASES & EVENTS
ARCHIVE

FDA acceptance enables pharmaceutical development partners to directly reference NorthStar no-carrier-added (n.c.a.) Ac-225 DMF in IND and NDA submissions NorthStar’s regulatory and cGMP manufacturing readiness materially strengthens assured supply availability for targeted-alpha therapies at clinical and commercial scale BELOIT, Wis., April 15, 2026 – NorthStar Medical Radioisotopes, LLC (NorthStar), a leading radiopharmaceutical company, today announced […]

Read more »

ATHENS, Greece & BELOIT, Wis., February 17, 2026 — BIOEMTECH, a developer of high-resolution PET and SPECT imaging systems for preclinical and translational research, today announced a strategic supply agreement with NorthStar Medical Radioisotopes (NorthStar) to secure a reliable supply and provide Actinium-225 (Ac-225) for use in preclinical studies conducted by BIOEMTECH customers. This agreement […]

Read more »

Purpose-built facility secures Convergent’s drug product manufacturing at the scale needed to meet late-stage CONV01-α clinical studies and commercial demand Expanded partnership designed to drive economies of scale across drug-product manufacturing and high-purity Actinium-225 (Ac-225) isotope production CAMBRIDGE, MA and BELOIT, WI, Jan. 6, 2026 — Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on […]

Read more »

First in industry to produce commercial-scale non-carrier-added (n.c.a.) Actinium-225 using electron-accelerator technology Product demonstrates high radionuclidic purity profile ensuring consistent performance in drug product radiolabeling and clinical development Scalable generator-based supply model capable of supporting global customers from first-in-human trials through commercial clinical supply BELOIT, Wis., January 6, 2026 – NorthStar Medical Radioisotopes, LLC (NorthStar), […]

Read more »

BELOIT, Wisconsin – December 17th, 2025 – NorthStar Medical Radioisotopes, LLC (NorthStar), a leading radiopharmaceutical company, today announced that Dr. Frank Scholz, President and Chief Executive Officer will present a company overview and update at the 44th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, January 14th at 2:00pm PT at […]

Read more »

BELOIT, Wis., December 16, 2025 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the appointment of Victor Miller as Chief Financial Officer, effective December 1st, 2025. With more than two decades of senior financial leadership in life sciences […]

Read more »

BELOIT, Wis., December 16, 2025 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the appointment of Kathy Spencer-Pike as Chief Commercial Officer, effective December 1st, 2025. In this role, Spencer-Pike will lead the company’s commercial strategy; overseeing sales, […]

Read more »

Multiple analytical methods were assessed to identify those yielding accurate quantification of Ac-225 radioisotope and drug product radiochemical purity BELOIT, Wis., October 3, 2025 – NorthStar Medical Radioisotopes LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, is pleased to announce that its experimental study […]

Read more »

• Enables cutting-edge collaborative clinical and translational research to accelerate new radiopharmaceutical drugs to market • Provides an integrated, one-stop expert resource to support all stages of drug development from concept to commercialization • Creates academic and real-world educational opportunities to help develop a skilled radiopharmaceutical talent pool and pipeline • Strengthens regional innovation and […]

Read more »

Unique combination of research excellence and manufacturing capability speeds treatments from lab to patient JANESVILLE, WI and BELOIT, WI – 9/23/2025 – A stretch of southern Wisconsin has developed into a significant hub for nuclear medicine innovation, combining breakthrough cancer research with the industrial infrastructure to manufacture and scale life-saving treatments. This region’s capabilities were […]

Read more »

BELOIT, Wis., August 11, 2025 – NorthStar Medical Technologies, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the appointment of Mr. Jon Coulter as Non-Executive Chairman. Mr. Coulter has been a Board Member of NorthStar since 2010 and was appointed to the […]

Read more »

BELOIT, Wis., August 7, 2025 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, announced that Gauri Gupta has joined the company as Vice President, Chief of Staff. In this role, Gupta will work closely with the CEO and NorthStar executive […]

Read more »

BELOIT, Wis., April 22, 2025 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, announced that Lori Mercurio has joined the company as Vice President, Corporate Strategy and Business Development. In this role, Mercurio will be responsible for conducting market and […]

Read more »

BELOIT, Wis., April 15, 2025 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, announced that Chris Hart, JD has joined the company as Vice President, Human Resources. In this role, Hart will be responsible for developing and implementing HR strategies […]

Read more »

• NorthStar to support the development of YAP Therapeutics’ innovative radiolabeled products • This collaboration merges the expertise and resources from both companies, including NorthStar’s state-of-the-art facilities • The agreement guarantees that YAP Therapeutics will receive clinical trial-ready doses of its novel products in development BELOIT, WI, and LAGUNA HILLS, CA – January 8, 2025 […]

Read more »

• NorthStar will supply non-carrier added Actinium-225, a radionuclide, for use with Ariceum’s first-in-class radiopharmaceutical drug, satoreotide Beloit, Wisconsin, and Berlin, Germany, December 11, 2024 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and Ariceum Therapeutics, a private biotech company […]

Read more »

NorthStar will provide PDRadiopharma, a wholly-owned subsidiary of PeptiDream, with a broad range of research and development services to support PeptiDream’s internal peptide-RI conjugate programs. Agreement provides PDRadiopharma access to NorthStar’s US campus-based global contract development and manufacturing capabilities and includes a master supply agreement for NorthStar’s actinium-225. BELOIT, Wis., KAWASAKI, Japan, December 5, 2024 […]

Read more »

NorthStar to provide non-carrier added actinium-225 (n.c.a. Ac-225) to Cellectar for use in its expanded portfolio of clinical programs This includes CLR 121225 an actinium-labeled phospholipid ether (PLE), expected to enter a Phase 1 study in pancreatic cancer in 2025 BELOIT, WI, November 21, 2024 – NorthStar Medical Radioisotopes, LLC today announced the signing of […]

Read more »

NorthStar will be the only U.S. based company to have co-located, commercial scale multi-radioisotope production and radiopharmaceutical manufacturing State-of-the-art facility will provide development services and dose manufacturing capacity for key medical radioisotopes, including Ac-225, Lu-177, Cu-64, Cu-67, and In-111, amongst others Purpose-built 52,000 sq ft facility serves as important milestone for the organization and the […]

Read more »

2nd Annual Oppenheimer Summit focused on Radiopharmaceutical Therapies in Oncology Frank Scholz, Ph.D., President and Chief Executive Officer of NorthStar will participate as expert panelist in “Supply Chain Challenges and Controversies – Ac-225 Availability, Pb-212 Logistics, The Last Mile” session BELOIT, Wis., and CAMBRIDGE, Mass., Oct 3, 2024 – NorthStar Medical Radioisotopes, LLC, a global […]

Read more »

NorthStar will supply Convergent’s CONV01-α clinical program with non-carrier added (n.c.a) Ac-225 supply The collaboration provides Convergent a unique opportunity to locate Ac-225 production and large-scale drug product manufacture at NorthStar’s single-campus U.S. facility ready for shipment to clinical sites NorthStar will provide Convergent research and development services to support process improvements and development of […]

Read more »

Agreement between NorthStar and major U.S. research institution aims to shift treatment paradigms and find a cure for a group of inflammatory diseases which affect small blood vessels in organs including the kidneys, lungs, skin and nervous system, among others Multi-faceted study will include projects focused on the use of radionuclides1 for diagnosis and treatment, […]

Read more »

Highlights: Multi-year supply agreement for radium-226 processing and purification Collaboration will work to provide Ac-225 for clinical trials and commercial supply Beloit, WI and OTTAWA, Ontario – July 22, 2024 – NorthStar Medical Radioisotopes, LLC (NorthStar) and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. (NYSE: BWXT) today announced that they have signed a […]

Read more »

Highlights: Builds on Companies’ respective core strengths Aligns intellectual property rights Establishes a long-term supply agreement under which NorthStar provides actinium-225 for Monopar’s development and potential future commercial programs WILMETTE, IL and Beloit, WI, June 11, 2024 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company, and NorthStar Medical Radioisotopes, LLC, a global innovator […]

Read more »

Company’s first fully equipped cleanroom facility to support batch production for radiopharmaceutical clinical trials was completed in 6 months Enables support functions and processes necessary to manufacture, release and ship a patient-ready final drug product at scale required for late-stage registration trials BELOIT, Wis., June 4, 2024 – NorthStar Medical Radioisotopes, LLC, a global innovator […]

Read more »

BELOIT, Wis., April 15, 2024 – NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following […]

Read more »

Highlights New Clinical Supply Agreement with Clarity for production of 67Cu-SAR-bisPSMA drug product ensures seamless product supply as Clarity pursues upcoming pivotal therapy trials NorthStar is uniquely able to provide large-scale U.S. manufacturing of both the therapeutic isotope (Cu-67) and cGMP radiopharmaceutical product ready for shipment to clinical sites NorthStar’s vertically integrated manufacturing offers significant […]

Read more »

BELOIT, Wis., April 4, 2024 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production, and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced that Frank Scholz, Ph.D., President and Chief Executive Officer will present at the upcoming 2024 Jefferies Radiopharma Innovation Summit. Presentation Details: Date: […]

Read more »

BELOIT, Wis., February 27, 2024 – NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February […]

Read more »

Highlights Long term, multi-year supply agreement provides Alpha-9 with NorthStar’s high purity non-carrier added (n.c.a.) Ac-225 to be used in Alpha-9’s targeted radiopharmaceutical programs for treatment of solid and liquid tumors Agreement will support Alpha-9’s ongoing development and clinical programs in addition to multiple undisclosed discovery-stage programs NorthStar is positioned to be one of the […]

Read more »

Highlights Collaboration expands August 2023 agreement under which NorthStar’s environmentally preferable, high purity n.c.a. Ac-225 will be used in Curadh’s molecularly targeted radiation (MTR) programs for treatment of solid tumors. Under the new agreement, NorthStar will manufacture and distribute patient doses for ongoing Curadh Ac-225 clinical studies and provide Ac-225 for commercial use upon NorthStar’s […]

Read more »

BELOIT, Wis., November 6, 2023 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used to detect and treat cancer, today announced that it will participate in the upcoming 2023 Truist Securities Biopharma Symposium being held November 8 to 9, 2023, in New York, NY. NorthStar executives Stephen […]

Read more »

Highlights NorthStar’s high purity non-carrier added (n.c.a.) Ac-225 to be used in Curadh’s molecularly targeted radiation (MTR) programs for treatment of solid tumors NorthStar is positioned to be the first commercial-scale producer of n.c.a. Ac-225 for advancing clinical research and commercial radiopharmaceutical therapy products BELOIT, Wis. And CHESTER SPRINGS, Pa., August 29, 2023 – NorthStar […]

Read more »

Highlights First participant of cohort 4 of the theranostic CL04 trial investigating 64Cu/67Cu SARTATE in neuroblastoma has been treated at the highest dose cohort of 375MBq/kg body weight using NorthStar’s electron accelerator-produced Cu-67, marking a key milestone in NorthStar’s agreement to exclusively supply Cu-67 to Clarity NorthStar now routinely produces high-activity, high specific-activity and high-purity […]

Read more »

−NorthStar’s non‐carrier added (n.c.a.) Ac‐225 to be used in Bayer’s radiopharmaceutical programs − BELOIT, Wis., July 18, 2023 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the signing of a supply agreement for the therapeutic medical radioisotope, actinium‐225 […]

Read more »

− NorthStar’s high purity non-carrier-added (n.c.a.) Ac-225 to be used in advancing Nucleus’ partners radioligand therapies to treat cancer − BELOIT, Wis. and ROCHESTER, Minn., June 27, 2023 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and Nucleus RadioPharma, a […]

Read more »

Highlights NorthStar is now producing high activity, high specific activity and high purity copper-67 (Cu-67 or 67Cu) suitable for Clarity’s ongoing clinical programs. Initial shipments by NorthStar for Clarity’s Targeted Copper Theranostic (TCT) clinical programs were completed under the exclusive supply agreement. Large-scale production of Cu-67 uses a highly efficient, environmentally preferable electron accelerator technology […]

Read more »

− Former Chief Executive Officer Stephen Merrick Appointed Executive Chairman − − Planned transition part of NorthStar’s strategy for continued growth and industry leadership in domestic radioisotope production and radiopharmaceutical development to meet needs of patients, pharmaceutical companies and radiopharmacies− BELOIT, Wis., June 19, 2023 – NorthStar Medical Technologies, LLC, a global innovator in the […]

Read more »

Beloit, Wis., May 9, 2023 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, today announced that it will be participating in the upcoming 2023 Guggenheim Radiopharmaceuticals Day. The event will be held in New York, NY, on May 15, 2023, […]

Read more »

BELOIT, Wis., April 18, 2023 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, has announced the appointment of Jean-Noel David, MBA, MS, as Vice President, Operations. In this new position, he brings more than 20 years of operational and leadership […]

Read more »

BELOIT, Wis., April 12, 2022 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, has announced the promotion of Jason Vinyard, MBA, MHA, to Vice President, Business Development, Therapeutic Technologies. Mr. Vinyard, who has been with NorthStar since 2021, was previously […]

Read more »

− Company positioned for continued strong growth in domestic radioisotope production and radiopharmaceutical development to meet needs of pharmaceutical companies, radiopharmacies and patients – − NorthStar’s Mo-99 program continues at the forefront of U.S. radioisotope production as the only commercialized producer of key medical radioisotopes molybdenum-99 (Mo-99)/technetium-99m (Tc-99m) − − Company poised as first commercial-scale […]

Read more »

Beloit, Wis., March 30, 2023 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, today announced that it will be presenting at the upcoming Jefferies Radiopharma Innovation Summit. The event will be held in New York, NY, on April 3, 2023. […]

Read more »

− NorthStar is poised to be the first commercial-scale producer of rare radioisotope, in chronic short supply, for use in clinical studies and patient healthcare to treat many types of cancer – BELOIT, Wis., March 1, 2023 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for […]

Read more »

WILMETTE, Ill. and BELOIT, Wis., Feb. 27, 2023 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, Ill.) and NorthStar Medical Radioisotopes, LLC (Beloit, Wis.), today announced an expansion of their radiopharmaceutical collaboration along with a new radiolabeled MNPR-101 imaging candidate designated as MNPR-101-Zr. Based on promising recently generated preclinical imaging results with MNPR-101-Zr showing high […]

Read more »

− Proprietary electron accelerator technology achieves “two beams on target” milestone, validating proof of concept for large-scale U.S. Mo-99 production without the use of uranium – − NorthStar has provided the only commercial, domestic U.S. supply of Mo-99 for more than four years; electron accelerator technology will increase production capability to nearly 40% of U.S. […]

Read more »

BELOIT, Wis. and SAN DIEGO, January 4, 2023 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and Inhibrx, Inc. (Nasdaq: INBX), a biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced a collaboration to […]

Read more »

November 18, 2022 Statement Attributable to: Frank Scholz, Ph.D., President and COO, NorthStar Medical Radioisotopes NorthStar Medical Radioisotopes, located in Beloit, Wisconsin, (“NorthStar”) recognizes the urgent medical need for technetium-99m (Tc-99m) to ensure patients have access to critical diagnostic imaging tests. Tc-99m is generated from molybdenum-99 (Mo-99) and used in over 40,000 patient studies per […]

Read more »

− Complements NorthStar’s growing radioisotope production programs, providing powerhouse combination of capabilities and expertise to advance patient care – − Full-scale CDMO services for collaborating companies designed to facilitate radiopharmaceutical development and commercialization in complex, highly regulated radiopharmaceutical sector – − NorthStar to be the first and only U.S. company housing commercial scale, multi-radioisotope production […]

Read more »

November 2, 2022 Statement Attributable to: Frank Scholz, Ph.D., President and COO, NorthStar Medical Radioisotopes NorthStar Medical Radioisotopes, located in Beloit, Wisconsin, recognizes the urgent medical need for technetium-99m (Tc-99m) to ensure patients have access to critical diagnostic imaging tests. Tc-99m is generated from molybdenum-99 (Mo-99) and used in approximately 40,000 patient studies per day […]

Read more »

Sydney, Australia and Beloit, Wisconsin, U.S. – October 26, 2022 — Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, and NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced they […]

Read more »

BELOIT, Wis. and Berlin, Germany, 11 October 2022 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and Eckert & Ziegler Isotope Technologies Dresden (ITD), a specialist for radiopharmaceutical plant engineering and fully owned subsidiary of Eckert & Ziegler AG (ISIN […]

Read more »

− NorthStar is further expanding commercial-scale domestic radioisotope production capabilities using IBA’s environmentally preferable Rhodotron® accelerator technology – BELOIT, Wis., USA and Louvain-La-Neuve, Belgium, September 20, 2022 – NorthStar Medical Radioisotopes, LLC (‘NorthStar’), a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and IBA (Ion Beam […]

Read more »

− NorthStar’s high purity non-carrier-added (n.c.a.) Ac-225 to be used in advancing Aktis Oncology’s pipeline of precision-engineered alpha radiotherapies to treat cancer − BELOIT, Wis., August 23, 2022 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the signing […]

Read more »

BELOIT, Wis., July 19, 2022 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the signing of a long-term supply agreement with Clovis Oncology, Inc. (NASDAQ: CLVS) for the therapeutic medical radioisotope, actinium-225 (Ac-225). Under terms of the agreement, […]

Read more »

BELOIT, Wis., June 20, 2022 – NorthStar Medical Technologies, LLC, a global innovator in the development, production and commercialization of diagnostic and therapeutic radiopharmaceuticals, today announced the promotion of one of its key executives. The announcement comes as NorthStar reaches a pivotal stage in its growth and industry influence. Dr. Frank Scholz has been named […]

Read more »

− Curie Therapeutics will be provided with priority access to NorthStar’s high purity non-carrier added (n.c.a.) Ac-225, which will be used to advance its multimodal pipeline of precision radiopharmaceuticals to address broad unmet needs in treatment of patients with solid tumors − BELOIT, Wis., and Cambridge, Mass., June 7, 2022 – NorthStar Medical Radioisotopes, LLC […]

Read more »

BELOIT, Wis., May 24, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the appointment of Monica Andersen as Vice President, Human Resources. In this new position, she will hold responsibility for the Company’s Human Resources and Organizational […]

Read more »

− NorthStar positioned for continued strong growth and setting leadership standards for domestic, environmentally sustainable radioisotope production across its portfolio to meet needs of health systems, radiopharmacies and patients – − NorthStar continues as the only U.S. commercial producer of diagnostic imaging radioisotopes non-uranium molybdenum-99 (Mo-99)/technetium-99m (Tc-99m), for more than three years − − Company […]

Read more »

− NorthStar’s high purity non-carrier-added (n.c.a.) Ac-225 to be used in Convergent’s lead, dual-targeted radionuclide program for prostate cancer, CONV01-α − BELOIT, Wis., and CAMBRIDGE, Mass., March 9, 2022 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and Convergent Therapeutics, […]

Read more »

BELOIT, Wis., March 8, 2022 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, today announced that Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes, will participate in an upcoming corporate event hosted by Oppenheimer & Co. Inc. […]

Read more »

BELOIT, Wis., November 29, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the appointment of Adam D. Lynch as Vice President, Corporate Development and External Affairs. In this new position, he brings to the Company more than […]

Read more »

BELOIT, Wis., USA and Louvain-La-Neuve, Belgium, November 18, 2021 – NorthStar Medical Radioisotopes, LLC (‘NorthStar’), a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announced a new contract in which NorthStar […]

Read more »

− Marking Company’s progress in advancing innovative and environmentally sound production of diagnostic imaging and therapeutic radioisotopes for the United States and Wisconsin − BELOIT, Wis., October 14, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, hosted a growth […]

Read more »

BELOIT, Wis., October 7, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, is proud to announce the launch of its newly redesigned corporate website. The new site includes increased functionality and a number of enhancements. Expanded content includes latest […]

Read more »

BELOIT, Wis. and INDIANAPOLIS, Ind., September 8, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today announced the signing […]

Read more »

BELOIT, Wis., September 8, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, today announced that Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes, will present at the H.C. Wainwright 23rd Annual Global Investment Conference, being held […]

Read more »

− Supports neutron capture and accelerator production technology to further increase NorthStar’s production capacity of commercially available non-uranium based Mo-99 − BELOIT, Wis., August 30, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, announced today that it has been […]

Read more »

− Collaboration will produce and distribute Iodine-123 (I-123) capsules, the proven radiopharmaceutical standard in diagnostic imaging studies for thyroid disease – BELOIT, Wis. and Arlington Heights, Ill., August 3, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, and GE […]

Read more »

BELOIT, Wis., June 21, 2021 – NorthStar Medical Technologies, LLC, a global innovator in the development, production and commercialization of diagnostic and therapeutic radiopharmaceuticals, today announced the appointment of Frank Scholz, Ph.D., as Senior Vice President and Chief Operating Officer. In this new position, he brings more than 20 years of relevant operational experience in […]

Read more »

BELOIT, Wis., June 10, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, being held in a virtual format from June 11 −15, 2021. NorthStar […]

Read more »

WILMETTE, Ill. and BELOIT, Wis., May 26, 2021 – Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, today announced the filing of a provisional composition of matter patent titled “Urokinase Plasminogen Activator Receptor-Targeted Radiopharmaceutical” covering a radiotherapeutic consisting of Monopar’s proprietary antibody MNPR-101 bound to Actinium-225 (Ac-225) via the metal binding agent PCTA. This […]

Read more »

− Master Supply Agreement encompasses clinical development and commercial supply for Clarity’s Cu-67-based candidates to treat neuroblastoma, breast and prostate cancers, among others − BELOIT, Wis. and Sydney, Australia – May 25, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical […]

Read more »

– Potential to significantly improve the yield of Actinium-based radiopharmaceuticals CHICAGO, Ill. and BELOIT, Wis., May 24, 2021 – Monopar Therapeutics Inc. (Nasdaq: MNPR) (Chicago, Ill) and NorthStar Medical Radioisotopes, LLC (Beloit, Wis), today announced the filing of a provisional patent with the U.S. Patent and Trademark Office (USPTO) titled “Bio-Targeted Radiopharmaceutical Compositions Containing Ac-225 and Methods […]

Read more »

− NorthStar, leading the way as the sole U.S. commercial supplier of molybdenum-99 (Mo-99), continues expansion efforts for increased capacity and ongoing reliable supply for diagnostic imaging − BELOIT, Wis., May 11, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic […]

Read more »

BELOIT, Wis., May 4, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, today announced that Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes, will present a corporate overview at the Emerging Medtech Summit 2021, on May […]

Read more »

− NorthStar has provided reliable molybdenum-99 (Mo-99)/technetium-99m (Tc-99m) supply for more than two years as the only U.S. commercial Mo-99 producer − Second NorthStar Mo-99 production and processing facility nearing completion ensuring even more reliable supply and additional Mo-99 production capability − RadioGenix® System sales continue growth, reliably providing hundreds of thousands of Tc-99m doses […]

Read more »

− Technetium-99m is the daughter isotope of molybdenum-99 (Mo-99) – − Collaboration enables integrating technology expertise to provide Tc-99m Generation Systems (TCM Generation Systems) that utilize non-uranium based Mo-99 produced using electron beam accelerators − − Diagnostic imaging studies using Tc-99m inform healthcare decisions for approximately 30 million patients annually around the world – BELOIT, […]

Read more »

− Organizational change positions NorthStar for next stage of growth and ongoing U.S. molybdenum-99 (Mo-99) production expansion − − NorthStar poised to be first commercial-scale supplier of important therapeutic radioisotopes Copper-67 (Cu-67) and Actinium-225 (Ac-225); Initial specialized SPECT imaging portfolio includes fibrin-targeted FibroScint, with potential indications in cardiovascular disease − BELOIT, Wis., March 3, 2021 […]

Read more »

BELOIT, Wis., March 2, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, today announced that Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes, will present at the H.C. Wainwright Global Life Sciences Conference, being held virtually […]

Read more »

− Concentrated molybdenum-98 (cMo-98) enables up to four-fold increase of critical medical radioisotope Mo-99 production in U.S. – − First and only commercial-scale application of innovative cMo-98 production technology – BELOIT, Wis., January 6, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radiopharmaceuticals used for medical imaging and […]

Read more »

Wilmette, IL, and Beloit, WI, December 10, 2020– Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing a urokinase plasminogen activator receptor targeted radio-immuno-therapeutic (uPRIT) for the potential treatment of severe COVID-19, today announced the selection of a uPRIT clinical candidate. Monopar and NorthStar partnered with IsoTherapeutics Group LLC to […]

Read more »

BELOIT, Wis. – December 8, 2020 – NorthStar Medical Technologies, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that it will participate in the upcoming Biotech Showcase™ 2021, being delivered digitally January 11 ‒ 15, 2021. Biotech Showcase is an investor conference focused on driving advances […]

Read more »

BELOIT, Wis., October 5, 2020 – NorthStar Medical Technologies, LLC, a global innovator in the development, production and commercialization of diagnostic and therapeutic radiopharmaceuticals, today announced the promotion of Chief Financial Officer Paul Estrem, to Executive Vice President. Mr. Estrem has also been appointed to the NorthStar Board of Managers, effective October 12, 2020, and […]

Read more »

BELOIT, Wis., September 17, 2020 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that Deputy Secretary of Energy Mark W. Menezes visited the Company’s Beloit, Wis. headquarters on September 11, 2020. His travel to Wisconsin underscored the Department of Energy’s commitment to […]

Read more »

WILMETTE, Ill., BELOIT, Wis. and TYLER, Texas, Sept. 09, 2020 – Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing urokinase plasminogen activator receptor targeted radio-immuno-therapeutics (uPRITs) for the potential treatment of patients with severe COVID-19, today announced a collaboration with The University of Texas Health Science Center at Tyler […]

Read more »

WILMETTE, Ill. and BELOIT, Wis. and ANGLETON, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI), who are collaborating on the development of Radio-Immuno-Therapeutics (RITs) to treat patients with severe COVID-19, today announced a partnership with IsoTherapeutics Group, LLC (Angleton, TX), to develop […]

Read more »

July 23, 2020 Statement Attributable to: Stephen Merrick, President and CEO, NorthStar Medical Radioisotopes NorthStar Medical Radioisotopes supplies a medically critical isotope pair, Mo-99 and Tc-99m, which is used in more than 40,000 U.S. diagnostic imaging procedures daily. Information provided by these scans informs the care and treatment of patients with heart disease and cancer, […]

Read more »

BELOIT, Wis. – July 8, 2020 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced its participation in the Society of Nuclear Medicine and Molecular Imaging (SNMMI) webinar, “Industry Outlook on Current and Future Mo-99 Supply.” James Harvey, PhD, Chief Scientific Officer of […]

Read more »

Chicago, IL and Beloit, WI, June 16, 2020 – Monopar Therapeutics Inc. (Nasdaq: MNPR) (Chicago, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI) announced today a 50/50 collaboration to develop potential Radio-Immuno-Therapeutics (RITs) to treat severe COVID-19 (patients with SARS-CoV-2 infection). Monopar is a clinical-stage biopharmaceutical company and NorthStar is a commercial producer and supplier […]

Read more »

– Award Recognizes Outstanding Contributions to Isotopes and Their Uses to Benefit Mankind – BELOIT, Wis., April 14, 2020 — NorthStar Medical Radioisotopes, LLC, a company involved in the production and distribution of radioisotopes used for medical imaging, today announced that it has received the President’s Award from the World Council on Isotopes (WCI). The […]

Read more »

March 19, 2020 Statement Attributable to: Stephen Merrick, President and CEO, NorthStar Medical Radioisotopes NorthStar Medical Radioisotopes supplies a medically critical isotope pair, Mo-99 and Tc-99m, which is used in more than 40,000 U.S. diagnostic imaging procedures daily. Information provided by these scans informs the care and treatment of patients with heart disease and cancer, […]

Read more »

Highlights include: Company marks reliable U.S. Mo-99 production and supply for customers despite ongoing domestic industry supply shortages FDA approval of RadioGenix System version 1.2 enhancements Initiatives for increased domestic Mo-99 production capacity on track: U.S. Food and Drug Administration (FDA)-approved Mo-99 filling lines; isotope processing and accelerator production facilities construction on schedule Strategic acquisition […]

Read more »

− Acquisition of technetium-99m (Tc-99m) SPECT agent expands company portfolio as strategic complement to commercially available RadioGenix® System − − Builds on NorthStar’s leadership expertise in development and commercialization of novel radiopharmaceuticals – − Exploratory Phase 1 study planned to investigate FibroScint (Tc-99m F4A) use in identifying thrombus in heart failure patients with assisted devices; […]

Read more »

− State-of-the art equipment to increase production efficiency and output for U.S.-based Mo-99 supply – Beloit, Wis., February 18, 2020 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that the U.S. Food and Drug Administration (FDA) has approved the addition of two […]

Read more »

BELOIT, Wis. and Sydney, Australia – February 11, 2020 – NorthStar Medical Technologies, LLC (NorthStar), a global innovator in the production and distribution of radioisotopes used for medical imaging, and Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, today announced the signing of a Letter of Intent for the commercial supply […]

Read more »

BELOIT, Wis. – January 21, 2020 – NorthStar Medical Technologies, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that it will participate in the upcoming Emerging Medtech Summit 2020 conference, being held February 18 ‒ 20, 2020, in Dana Point, Ca. The Emerging Medtech Summit 2020 […]

Read more »

BELOIT, Wis. – December 16, 2019 – NorthStar Medical Technologies, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that it will participate in the upcoming Biotech Showcase™ 2020, being held January 13 ‒ 15, 2020, in San Francisco, Ca. Biotech Showcase is an investor conference focused […]

Read more »

− RadioGenix® Systems have enabled reliable technetium 99m (Tc-99m) supply for patients’ diagnostic imaging procedures since product launch, despite ongoing industry supply shortages – Beloit, Wis., November 27, 2019 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, announced a landmark for its RadioGenix System […]

Read more »

– Marking NorthStar expansion progress to increase U.S. production of non-highly enriched uranium produced molybdenum-99 (Mo-99), used in producing important medical isotope technetium-99m (Tc-99m) ‒ ‒ Recognizing RadioGenix® System contributions in addressing ongoing Mo-99 supply shortages by providing customers with nearly a year of continuous medical radioisotope supply since launch ‒ Beloit, Wis., October 14, […]

Read more »

‒ Voting Begins September 9, 2019 at www.madeinwis.com ‒ Beloit, Wis., September 9, 2019 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced its participation in the 4th Annual Coolest Thing Made in Wisconsin contest. The event highlights Wisconsin’s vibrant manufacturing industry, its […]

Read more »

‒ Panel to discuss domestic Tc-99m radioisotope production, role of nuclear diagnostics and treatments in advancing personalized medicine – BELOIT, Wis. – August 28, 2019 – NorthStar Medical Technologies, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that it will participate in the upcoming Atoms for […]

Read more »

Beloit, Wis. and W. Lafayette, Ind., August 20, 2019 – NorthStar Medical Radioisotopes, LLC and Purdue University’s College of Pharmacy today announced a collaborative agreement which expands the College of Pharmacy’s nuclear pharmacy training program. As part of the collaboration, NorthStar has provided a RadioGenix® System to the College of Pharmacy for use in training […]

Read more »

– Supports enhancements for commercially available RadioGenix® System and technology to increase NorthStar’s current production capacity of non-uranium based Mo-99 – BELOIT, Wis. – July 23, 2019 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that it has been awarded $15 million […]

Read more »

─ Facility part of staged, dual production pathway plan to expand Mo-99 production and efficiency in parallel with RadioGenix® System enhancements ─ RadioGenix System customers provided with reliable Mo-99 supply throughout eight months since commercial launch, helping mitigate concurrent industry disruptions BELOIT, Wis. – July 16, 2019 – NorthStar Medical Radioisotopes, LLC, a global innovator […]

Read more »

BELOIT, Wis. – June 12, 2019 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced upcoming presentations at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI), from June 22 – 26, 2018 in Anaheim, Ca. Presentation topics encompass ongoing domestic […]

Read more »

BELOIT, Wis. – April 23, 2019 – NorthStar Medical Technologies, LLC, (“NorthStar” or the “Company”) a global innovator in the production and distribution of radioisotopes used for medical imaging and therapy, today announced the closing of a $100 million secured financing with funds managed by Oberland Capital Management LLC (“Oberland Capital”). NorthStar received $75 million […]

Read more »

– Accelerator technology key component of NorthStar’s multi-pronged Mo-99 production strategy – BELOIT, Wis. – March 29, 2019 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, and IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment […]

Read more »

– Positive RadioGenix System market momentum continues – – Increasing weekly domestic production of non-uranium based Mo-99 – Highlights include: Strategically-planned RadioGenix System roll out on track; initial units in use Numerous RadioGenix System commercial sites in regulatory licensure review process; many additional sites anticipated in 2019 Every week, an increasing number of technetium-99m (Tc-99m) […]

Read more »

BELOIT, Wis. – December 18, 2018 –NorthStar Medical Technologies, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced the appointment of Paul Estrem, CPA, as Senior Vice President and Chief Financial Officer. Mr. Estrem holds financial responsibility for the operations of company, reporting to President and Chief […]

Read more »

– Award for Outstanding Achievement presented at 2018 Molybdenum-99 Topical Meeting – Beloit, Wis., October 1, 2018 – NorthStar Medical Radioisotopes, LLC, a company involved in the production and distribution of radioisotopes used for medical imaging, today announced that it received an Award for Outstanding Achievement from the U.S. Department of Energy’s National Nuclear Security […]

Read more »

– Former Chairman and CEO George Messina named Chairman Emeritus; appointed President and Chief Executive Officer of NorthStar Nuclear Therapies LLC – – Diane Hendricks appointed as Chairperson of the Board – BELOIT, Wis. – Sept. 14, 2018 – The Board of Managers of NorthStar Medical Technologies, LLC (“NorthStar” or the “Company”), a global innovator […]

Read more »

– Approval enables expanded manufacturing capacity and supports commercial launch of RadioGenix Systems to produce critically important diagnostic imaging radioisotope technetium-99m from domestic, non-uranium based molybdenum-99 – BELOIT, Wis. – July 24, 2018 – NorthStar Medical Radioisotopes, LLC (NorthStar), a company involved in the production and distribution of radioisotopes used for medical imaging, today announced […]

Read more »

BELOIT, Wis. – June 19, 2018 – NorthStar Medical Radioisotopes, LLC (NorthStar), a company involved in the production and distribution of radioisotopes used for medical imaging, today announced that it will participate in a panel session on molybdenum-99 (Mo-99) supply at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI), from June 23 […]

Read more »

BELOIT, Wis. – June 18, 2018 – NorthStar Medical Technologies (NorthStar), a company involved in the development, production and distribution of radioisotopes for medical imaging and therapeutics, today provided a progress update on its actinium-225 (Ac-225) radioisotope program. Ac-225 is a high energy alpha-emitting radioisotope with potential therapeutic applications as a Targeted Alpha Therapy (TAT) […]

Read more »

– Event recognizes recent U.S. Food and Drug approval of NorthStar’s RadioGenix™ System for use in producing the widely used medical isotope technetium-99m (Tc-99m) from non-uranium produced molybdenum-99 (Mo-99), the first domestic production in more than 25 years – BELOIT, Wis. – April 30, 2018 – NorthStar Medical Radioisotopes, LLC (NorthStar), a company involved in […]

Read more »

– Enables domestic Mo-99 supply produced without uranium for U.S. healthcare – – First U.S. source of medical radioisotope Mo-99 in more than 25 years – BELOIT, Wis. – February 8, 2018 – NorthStar Medical Radioisotopes, LLC, (NorthStar) a company involved in the production and distribution of radioisotopes used for medical imaging, today announced that the U.S. Food […]

Read more »

Holst has more than 25 years of sales and marketing experience in the pharmaceutical and medical imaging industries, most recently as senior director of marketing at Navidea Biopharmaceuticals. She joins NorthStar as it advances toward U.S. Food and Drug Administration (FDA) approval of its RadioGenix™ intelligent isotope separation system and its non-fission, non-uranium-based brand of […]

Read more »

BELOIT, Wis. – NorthStar Medical Technologies LLC, parent company of NorthStar Medical Radioisotopes LLC, has received additional matching funds from the U.S. Department of Energy’s National Nuclear Security Administration (DOE/NNSA), bringing to $11.1 million the total funded for NorthStar Medical Radioisotopes’ accelerator method of producing the medical radioisotope molybdenum-99 (Mo-99). The award supports the process’ […]

Read more »

ST. LOUIS (Sept. 13, 2016) – At the National Nuclear Security Administration’s (NNSA) 2016 Mo-99 Topical Meeting in St. Louis, NorthStar Medical Radioisotopes LLC Senior Vice President and Chief Science Officer James Harvey, Ph.D. will report on the company’s progress toward establishing a domestic supply of the medical radioisotope molybdenum-99 (Mo-99) produced without the use […]

Read more »

BELOIT, Wis. (Sept. 12, 2016) – NorthStar Medical Radioisotopes LLC has hired James Brodack as vice president of regulatory affairs/quality assurance and Rim Milunas as vice president of engineering. Brodack oversees day-to-day regulatory and quality operations at NorthStar. Milunas spearheads research and development. product design and engineering, with a strong focus on product development and […]

Read more »

BELOIT, Wis. (June 10, 2016) – NorthStar Medical Radioisotopes LLC has been awarded three patents and a trademark approval from the United States Patent and Trademark Office. Patents were granted for the RadioGenix™ isotope separation system and two of its key components – the Molybdenum-99 (Mo-99) Source Vessel and the Technetium-99m (Tc-99m) Product Cartridge. A […]

Read more »

BELOIT, Wis. – NorthStar Medical Radioisotopes LLC is enhancing its production operations at the University of Missouri Research Reactor (MURR) in Columbia, Missouri, adding a new filling line that will quadruple the company’s capacity there to dispense the medical radioisotope molybdenum-99 (Mo-99). NorthStar has contracted with Von Gahlen International Inc. to design and install the system, which will include […]

Read more »

BELOIT, Wis. – Stephen Merrick has joined NorthStar Medical Radioisotopes LLC as Senior Vice President and Chief Operating Officer, a newly created position with the company. Merrick brings 24 years of experience in the biotechnology/pharmaceutical/life sciences sector, having held multiple executive positions with leading global companies. He will oversee day-to-day operations at NorthStar – including engineering, production and customer […]

Read more »

MADISON, Wis. – NorthStar Medical Radioisotopes LLC has received $11.75 million from the U.S. Department of Energy’s (DOE) National Nuclear Security Administration (NNSA) for continued development and commercialization of two technologies to produce the medical radioisotope molybdenum-99 (Mo-99) without the use of highly enriched uranium (HEU). NNSA provided $8.86 million to support NorthStar’s neutron capture production process and $2.89 million for the company’s accelerator production process. […]

Read more »

MADISON, Wis. – NorthStar Medical Radioisotopes LLC and the Westinghouse Electric Company LLC have completed a memorandum of understanding under which the companies will explore the potential for producing medical radioisotopes in commercial nuclear reactors. Of particular interest is the generation of molybdenum-99 (Mo-99) via the irradiation of molybdenum-98 (Mo-98) in the commercial nuclear reactor core. This collaboration is […]

Read more »

MADISON, Wis. – NorthStar Medical Radioisotopes LLC has received approval to begin routine production of molybdenum-99 (Mo-99) at the University of Missouri Research Reactor (MURR) facility in Columbia, Mo. The company will now be able regularly operate its proprietary aliquoting system at the MURR site to fill source vessels with Mo-99, enabling the company to establish a weekly production […]

Read more »

MADISON, Wis. – NorthStar Medical Radioisotopes LLC has completed its first production-scale test run of the molybdenum-99 (Mo-99) aliquoting system installed at the University of Missouri Research Reactor (MURR) in Columbia, Missouri. The test and subsequent shipment of the resulting Mo-99 to NorthStar’s Madison facility is another milestone in the establishment of domestic production of the vital medical radioisotope. […]

Read more »

MADISON, Wis. – James Harvey, Ph.D., senior vice president and chief science officer of NorthStar Medical Radioisotopes LLC, will be a featured speaker at the American Pharmacists Association Annual Meeting & Exposition (APhA2015) in San Diego later this month, highlighting new technologies and techniques that will create a commercially viable domestic supply of the medical radioisotope molybdenum-99 (Mo-99). Harvey […]

Read more »

MADISON, Wis. – NorthStar Medical Radioisotopes LLC has been awarded $5.2 million in additional funding by the U.S. Department of Energy’s (DOE) National Nuclear Security Administration (NNSA). The grant supports the continued development and commercialization of the company’s neutron capture process for producing the medical radioisotope molybdenum-99 (Mo-99) without the use of highly enriched uranium (HEU). Under the terms of the cooperative agreement […]

Read more »

Madison, Wis. – August 14, 2014 – NorthStar Medical Radioisotopes LLC has signed a non-exclusive letter of intent with GE Healthcare, a division of General Electric Company (NYSE: GE), marking further progress toward establishing the first existing commercially viable domestic source of the radioisotope 99molybdenum (99Mo). 99Mo is the parent isotope of 99mtechnetium (99mTc), the most widely […]

Read more »

BELOIT, Wis. – July 22, 2014 – NorthStar Medical Radioisotopes LLC broke ground today for a new 50,000-square-foot facility at 1800 Gateway Blvd. in Beloit, Wis. When completed in late 2014, the facility will house the company’s headquarters and activities related to the production of the medical radioisotope molybdenum-99 (Mo-99). Video Courtesy WKOW News NorthStar Medical Radioisotopes Breaks Ground […]

Read more »

WASHINGTON, D.C. – July 15, 2014 – NorthStar Medical Radioisotopes LLC is making continued progress towards establishing a commercially viable domestic supply of the radioisotope molybdenum-99 (Mo-99), according to NorthStar’s chief science officer, James T. Harvey, Ph. D. Harvey provided an update on NorthStar’s progress in two presentations at the 2014 Mo-99 Topical Meeting here, […]

Read more »

MADISON, Wis. – June 30, 2014 – NorthStar Medical Radioisotopes LLC has signed a pledge with the Preparatory Commission for the Comprehensive Nuclear-Test-Ban Treaty Organization (CTBTO) designed to help the CTBTO detect nuclear testing. In signing the Radioxenon Emissions Pledge, NorthStar stated that its production of the medical radioisotope molybdenum-99 (Mo-99) does not result in the emission […]

Read more »

ST. LOUIS, MO – June 7, 2014 – Signaling progress in the drive to launch the first commercially-viable domestic source of non-HEU materials, NorthStar Medical Technologies, LLC today announced the signing of a non-exclusive Letter of Intent with Triad Isotopes, Inc.  The agreement solidifies Triad’s position as an early adopter of domestically-sourced Non-HEU Molybdenum99 through […]

Read more »

MADISON, WI – November 21, 2013 – NorthStar Medical Technologies, LLC (“NorthStar”), today announced it was awarded a $21.8 million cooperative agreement of which $10.9 million will be funded by the Department of Energy’s (DOE) National Nuclear Security Administration (NNSA). The cooperative agreement is part of the NNSA’s Global Threat Reduction Initiative, which aims to […]

Read more »

MADISON, WI – September 17, 2013 – NorthStar Medical Technologies, LLC (“NorthStar”), a manufacturer and distributor of domestically-produced radioisotopes for the nuclear medicine industry, today announced the closing of a financing round totaling $13.5 million. The round was led by NorthStar’s lead investor, Hendricks Holding Company, Inc., and a group of accredited local investors. Proceeds […]

Read more »

MADISON, WI – March 20, 2013 – NorthStar Medical Technologies, LLC, (NorthStar) announced that it has submitted a New Drug Application (NDA) with the Food and Drug Administration (FDA).  The FDA has accepted the application for review.  The submission is for NorthStar’s TechneGen™ Generator System, which will allow nuclear pharmacies to process radioisotopes for critical medical […]

Read more »

MADISON, WI. – November 15, 2012 – NorthStar Medical Radioisotopes, LLC (NorthStar), today announced that it has been awarded $22.2 million in federal funding in a Phase 2 cooperative agreement through the National Nuclear Security Administration’s (NNSA) Global Threat Reduction Initiative. The cooperative agreement marks successful completion of an Environmental Assessment of NorthStar’s proposed Beloit, Wis. facility. […]

Read more »

MADISON, WI – September 26, 2012 – NorthStar Medical Technologies, LLC (NorthStar), today announced that it has signed an agreement with Hendricks Commercial Properties, LLC (HCP) to develop a state-of-the-art medical isotope production facility in the Gateway Business Park of Beloit, Wisconsin. The facility will be built to suit for lease. Once complete, the facility […]

Read more »

MADISON, WI – September 5, 2012 – NorthStar Medical Technologies, LLC (NorthStar), a manufacturer and distributor of domestically-produced radioisotopes for the nuclear medicine field, today announced the closing of a Series D preferred stock financing round totaling $5.2 million. Stateline Angel Investors of Rockford, Illinois, was the lead investor, joined by existing NorthStar investor Hendricks […]

Read more »

(MADISON, Wis. – Nov. 1, 2011) – NorthStar Medical Radioisotopes, LLC (NMR) has signed a follow on cooperative agreement totaling $4.6 million with the National Nuclear Security Administration’s (NNSA) Global Threat Reduction Initiative for the company’s medical isotope production program. The cooperative agreement will be funded under a 50-50 cost share arrangement between NMR and […]

Read more »

WILMINGTON, N.C.—September 12, 2011—To help address a shortage of molybdenum-99 (Mo-99), a medical isotope used in millions of medical procedures each year, GE Hitachi Nuclear Energy (GEH) and Exelon have joined to study the feasibility of producing Mo-99 at Clinton Power Station, a nuclear power plant in Clinton, Ill. Mo-99 decays into technetium-99m, an isotope […]

Read more »

MADISON, Wis. –Sept. 8 —   NorthStar Medical Radioisotopes was among six Wisconsin bioscience companies to be selected as the winners of BioForward’s 2011 Emerging Company Showcase. The showcase is part of the 2011 Bioscience Vision Summit, hosted by BioForward, the member-driven state association that is the voice of Wisconsin’s bioscience industry. The Emerging Company Showcase […]

Read more »

(MADISON, WI. – April 7, 2011) – NorthStar Medical Radioisotopes, LLC (NorthStar) announced it has received an investment from Hendricks Holdings of Beloit, WI. The investment will allow NorthStar to rapidly pursue introduction of new technologies and production methodologies in the nuclear medicine market for molybdenum-99 and other medically significant radioisotopes. Molybdenum-99 is used to […]

Read more »

(MADISON, WI. – March 1, 2011) – NorthStar Medical Radioisotopes, LLC (NorthStar) announced it has signed an agreement with the University of Missouri Research Reactor (MURR) to supply NorthStar with low specific activity molybdenum-99. This agreement allows NorthStar to ramp up over time to 3,000 6-day curies per week. Production operations are expected to begin […]

Read more »